The company will be able to use these newly patented components to manufacture an optimized vaccine against beta-amyloid, the peptide responsible for the onset of Alzheimer’s disease. The tolerability of the first Affiris vaccine, Affitope AD01, is currently being tested as part of a Phase I clinical trial.
Walter Schmidt, CEO of Affiris, said: “This patent is an ideal addition to the Affiris patent portfolio. Our protected Affitome technology enables us to target the relevant structures of human rogue proteins. Our individual active substances are known as Affitope, while the entire spectrum of possible substances is referred to as Affitome.
“This new patent grants us the commercial rights of use for this technology in relation to Alzheimer’s disease. Furthermore, Affiris is now the only company entitled to develop an optimized Alzheimer’s vaccine that will overcome the problem of potential autoimmune reaction.”